Jetema signs ₩30.2bn drug supply contract with domestic distributor

Jetema · KOSDAQ · 216080 · Oct 15, 2026 · Supply contracts

Jetema filed a supply contract, Pharmaceutical (Botulinum Toxin) Exclusive Supply, with a domestic distribution company. The contract amount is ₩30.2bn, reported as 39.7% of revenue, for a period from Oct 14, 2026 to Oct 14, 2031.

Key facts

Contract namePharmaceutical (Botulinum Toxin) Exclusive Supply
CounterpartyDomestic distribution company
Contract amount₩30.2bn
% of revenue (as reported)39.7%
Period startOct 14, 2026
Period endOct 14, 2031

Comparison

Amount as % of FY2025 revenue (calculated)39.2%
Revenue 2025₩76.9bn
Revenue 2024₩68.5bn
Revenue 2023₩58.7bn

Context

In the 12 months before this filing, Jetema filed 2 supply contracts totaling ₩34.9bn. By our calculation, this contract equals 39.2% of FY2025 revenue of ₩76.9bn.

Key metrics

Supply contracts

Supply contracts, last 12 months₩75.1bn As of Oct 15, 2026 Source 1 ↗, Source 2 ↗, Source 3, Source 4
Supply contracts vs prior-year revenue97.6% As of Oct 15, 2026 Source 1 ↗, Source 2 ↗, Source 3, Source 4
Contracts without a KRW amount0 contracts without a KRW amount excluded As of Nov 19, 2026

Related filings

Source: DART (Financial Supervisory Service) · Original filing on DART ↗ (opens the Financial Supervisory Service's DART site)